Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for Postvitrectomy Diabetic Vitreous Hemorrhage with NVG
NCT02647515Phase 4Completed
- Sponsor
- Ruijin Hospital
- Start
- Jan 2013
- Primary completion
- Dec 2014
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 4 trial of ranibizumab in neovascular glaucoma (NVG), vitreous hemorrhage secondary to proliferative diabetic retinopathy (DVH), sponsored by Ruijin Hospital. Started Jan 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular glaucoma (NVG)vitreous hemorrhage secondary to proliferative diabetic retinopathy (DVH)
Beyond the preview
Go deeper on NCT02647515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02647515.